Industry News
Zenyth licence to boost antibody targets
Zenyth Therapeutics (ASX:ZTL), formerly Amrad, has taken a licence from Massachusetts-based Dyax Corp, to use the US company's proprietary phage display libraries to develop antibody therapeutics for inflammation and cancer. [ + ]
HLS5 Gene implicated in Huntington's
The Western Australian Institute for Medical Research (WAIMR) has discovered a link between the HLS5 gene and key aspects of Huntington’s disease and AIDS development, according to an announcement made by BioPharmica.
[ + ]Eppendorf South Pacific relocates
Eppendorf South Pacific has relocated its facilities to larger offices in North Ryde to support the company's continuing growth. The new address for Eppendorf South Pacific is Unit 4, 112 Talavera Road, North Ryde 2113. Ph: (02) 9889 5000 and fax: (02) 9889 5111 remain unchanged.
[ + ]Tissue Therapies to repeat animal trial
Brisbane biotech Tissue Therapies (ASX:TIS) will repeat an animal trial designed to gather data to optimise its wound treatment VitroGro for human clinical trials following independent review of the results. [ + ]
Russia recommends approval of Solagran liver disease drug
The Russian Ministry of Health has recommended the approval of Melbourne-based Solagran's (ASX:SLA) Ropren, the finished form of Bioeffective R, as a treatment for chronic liver disease. [ + ]
Norwood Abbey to test virosomal delivery
Norwood Abbey (ASX:NAL) has initiated animal studies for the use of its needle-free injection device for delivering virosomes, potent carriers of antigens for vaccination. [ + ]
Mimotopes and Genzyme Pharmaceuticals to collaborate
PharmAust's (ASX:PAA) subsidiary Mimotopes and US-based Genzyme Corporation have signed a strategic alliance agreement to provide a total suite of peptide products and services to both companies' customer bases. [ + ]
BresaGen executes supply contracts
Adelaide biotechnology manufacturer BresaGen (ASX:BGN) has executed supply contracts worth AUD$680,000 with WA based junior biotech Caldeon and Brisbane's Tissue Therapies (ASX:TIS). [ + ]
Separation technology wins award
Collaboration between the University of Newcastle and Ludowici MPE, which led to the development of a new separation technology, has won a national award for Best Research and Development.
[ + ]Ian Frazer named Australian of the Year
Prof Ian Frazer, inventor of the world's first cancer vaccine, Gardasil, has been named Australian of the Year. [ + ]
PolyNovo in $11m deal with Medtronic
PolyNovo Biomaterials, jointly owned by CSIRO and Xceed Biotechnology (ASX:XBL) has signed a partnering and licensing agreement potentially worth more than AUD$11 million with giant US-based device maker Medtronic. [ + ]
Epitan opts for name change
Melbourne-based Epitan (ASX:EPT) is planning to change its name to Clinuvel Pharmaceuticals. [ + ]
New Peptech CEO excited by Australian opportunities
John Chiplin, the new CEO of Sydney biopharma Peptech (ASX:PTD), sees strong similarities between the state of Australia's biotechnology industry and California's nascent biotechnology industry in San Diego in the mid-1980s. [ + ]
Apollo completes phase Ib psoriasis trial data collection
Sydney-based biopharma Apollo Life Sciences (ASX:AOP) said no significant adverse side-effects were detected in a phase Ib trial of its topical psoriasis cream, developed from human-expressed protein. [ + ]
BioProspect raises $1.2m
Natural pesticide developer BioProspect (ASX:BPO) has raised AUD$1.2 million from its fully underwritten rights offer, where shareholders could subscribe for one new share, at a price of $0.02, and a free attaching option for every three shares held. [ + ]
